Chartsbank is a comprehensive database containing information on more than 3000 new drugs in development, inclusive of pre-clinical research up to phase IV development

Subscribers view details.


 
Please Select Filter Criteria for the drug pipeline
Drug Pipeline by drug name:
Drug Pipeline by Company:
Drug Pipeline by Disease:

Subscribe

Drug Pipeline by Generic :
Drug Pipeline by Current Status:
Drug Pipeline by ICN:

...21222324252627282930...
CompanyDrug NameStatusIndication Group
NeuTec Pharma Mycograb Submitted for approval in EUAnti-infectives for systemic use
Astellas Pharma Mycamine Submitted for approval in Japan and EU, approved in USAAnti-infectives for systemic use
AVAX Technologies M-vax in Phase IIIAntineoplastic & immunomodulating agents
Bavarian Nordic MVA-BN polytope in Phase IIAnti-infectives for systemic use
Bavarian Nordic MVA-BN HIV nef in Phase IIAnti-infectives for systemic use
Viragen Multiferon Approved in N/AAntineoplastic & immunomodulating agents
Sanofi-aventis MULTAQ discontinuedCardiovascular system
Adams Respiratory Therapeutics Mucinex DM Approved in USARespiratory system
Adams Respiratory Therapeutics Mucinex D Approved in USARespiratory system
Pozen MT-300 discontinuedNervous system
Genzyme MOZOBIL accomplished Phase IIIAntineoplastic & immunomodulating agents
Accera miroslav.braikov@gmail.com miroslav.braikov@gmail.comAlimentary tract & metabolism
Amarin Miraxion accomplished Phase IIINervous system
CollaGenex Metastat accomplished Phase IIAntineoplastic & immunomodulating agents
AstraZeneca Merrem Approved in USAAnti-infectives for systemic use
Chiron MeNZB Approved in New ZealandAnti-infectives for systemic use
Bayer Menostar Approved in USAGenito urinary system & sex hormones
Chiron Menjugate accomplished Phase IIIAnti-infectives for systemic use
Baxter International Mening C Vaccine Various Submitted for approval in EUAnti-infectives for systemic use
Chiron MenB accomplished Phase IAnti-infectives for systemic use
...21222324252627282930...




Drug Pipeline Copyright © 2005- 2017 All Rights Reserved.